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bidirectional (depression), and co ‑occurrence by 
chance.5 
A number of population ‑based and case ‑control 
studies have reported an inceased risk of medi‑
cal and psychiatric conditions in patients with 
epilepsy.6-9 Such patients with comorbidities are 
at higher risk of poor seizure outcome, pharma‑
cokinetic interactions, reduced quality of life, in‑
creased health care needs, and premature mor‑
tality.5 Early identification and adequate treat‑
ment of comorbid conditions are indispensable 
for the appropriate management of both epilep‑
sy and comorbidities. Geographic, environmental, 
and socioeconomic factors (eg, ethnicity, the geo‑
graphic distribution of the disease, and quality 
and availability of health care services) may in‑
fluence the nature and prevalence of somatic co‑
morbidities in patients with epilepsy. 
INTRODUCTION Epilepsy is one of the most com‑
mon chronic neurological disorders. The point 
prevalence of the active disease is 6.38 per 1000 
persons in Poland; thus, it is estimated to affect 
approximately 250 000 people in Poland (Sta‑
tistics Poland).1,2 The burden of epilepsy is asso‑
ciated not only with seizures and antiepileptic 
medication but also with a wide range of somat‑
ic and psychiatric comorbidities and their treat‑
ment.3 The term “comorbidity,” originally coined 
by Feinstein, refers to the greater than coinciden‑
tal co ‑occurrence of 2 conditions in the same per‑
son.4 Several mechanisms of the association be‑
tween epilepsy and comorbid conditions have 
been proposed: causative (eg, stroke and brain tu‑
mor), resultant (eg, seizure ‑related fractures and 
treatment ‑related psychiatric disorders), shared 
risk factors (eg, migraine and cerebral palsy), 
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ABSTRACT
INTRODUCTION A wide spectrum of somatic and psychiatric disorders occurs frequently in patients 
with epilepsy, which adds to the burden of this disease.
OBJECTIVES The aim of the study was to estimate the prevalence and risk factors of somatic comorbidi‑
ties and analyze somatic comedication in adult patients with epilepsy.
PATIENTS AND METHODS This study involved patients with epilepsy treated in university epilepsy clinic. 
Data on epilepsy, antiepileptic drugs (AEDs), somatic comorbidities, and their treatment were collected 
from a structured interview and from medical records.
RESULTS The sample population consisted of 636 patients (mean age, 35.3 years); 380 (59.7%) were 
female and 241 (37.9%) had well ‑controlled epilepsy. At least 1 comorbid somatic condition was found 
in 216 patients (34%). The most prevalent somatic comorbidities were cardiovascular diseases, aller‑
gies, migraine, hyperlipidemia, thyroid disorders, and chronic lower respiratory diseases. Furthermore, 
200 patients (31.4%) were prescribed at least 1 medication for somatic disorders. Logistic regression 
analysis revealed several independent risk factors for the occurrence of somatic comorbidities: older 
age, shorter duration of epilepsy, lower seizure frequency, and lower number of AEDs.
CONCLUSIONS Somatic comorbidities and comedication with non ‑AEDs were found in one ‑third of 
the relatively young cohort of adult patients with epilepsy. Patients with pharmacoresistant epilepsy may 
be at risk of underdiagnosis and undertreatment of somatic comorbidities. The presence of comorbidi‑
ties may have implications for the diagnosis and treatment of seizure disorder and coexisting condition.
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Epilepsy classification, according to the history, 
neurological examination, electroencephalogra‑
phy, and neuroimaging (magnetic resonance im‑
aging or computed tomography).11 Antiepileptic 
drugs (AEDs) and their doses used at the time 
of the interview were recorded.
At a baseline visit, patients were asked to com‑
plete the questionnaire related to the comorbid‑
ities and chronic use of medications. They were 
also requested to bring all their current medica‑
tions and available medical records for the sub‑
sequent visit. These data were used to verify and 
to supplement previous information recalled by 
the patients. Comorbid conditions were classified 
according to the International Statistical Classifi‑
cation of Diseases and Related Health Problems, 
Tenth Revision; medications were classified ac‑
cording to the Anatomical Therapeutic Chemical 
classification system.12,13 Mental and behavior‑
al disorders, diseases of the eye and adnexa, and 
diseases of the ear and mastoid process were ex‑
cluded from the analysis.
In this study, we followed the principles of 
the Helsinki Declaration, and the protocol was 
approved by the Bioethical Committee of Jagiel‑
lonian University, Kraków. Each patient was in‑
formed about the aims and methods of this study, 
and they provided their written consent to par‑
ticipate in this study.
Statistical analysis Qualitative variables were 
presented as numbers and percentages. Quan‑
titative variables were described using descrip‑
tive statistics: mean, median, standard deviation 
(SD), minimum, and maximum. Significant dif‑
ferences between the subgroups for quantitative 
variables were verified using the nonparametric 
Mann–Whitney test. Verification of dependen‑
cies between categorical variables was calculated 
using the Pearson χ2 independence test. The sig‑
nificance of differences between percentages for 
specific pairs of cases was verified using the signif‑
icance test of differences for the structured index. 
The second part of the analysis included the analy‑
sis of the logistic regression model for those factors 
that in the univariate analysis showed significant 
differences between the groups having at least 1 
somatic comorbidity and that without somatic co‑
morbidity. The model was created using backward 
stepwise regression. A significance level of 0.05 was 
assumed. Statistical analysis was performed using 
the Statistica version 12.5 software (StatSoft Inc., 
Tulsa, Oklahoma, United States).
RESULTS Sample characteristics A total of 636 
adult patients participated in this study. The mean 
(SD) age of patients was 35.3 (13.6) years. Of 
these, 380 (59.7%) were female and 241 (37.9%) 
were in remission (less than 1 seizure per year). 
The  mean (SD) age at  onset of epilepsy was 
19.5 (14.6) years. The clinical characteristics of 
the studied group, including age, sex, age at onset 
of epilepsy, type of epilepsy, frequency of seizures, 
and currently used AEDs, are shown in TABLE 1.
To the best of our knowledge, Polish centers 
have not evaluated chronic medical disorders in 
patients with epilepsy. Therefore, we decided to 
study somatic comorbidities, their prevalence, 
and risk factors and to analyze the extent of so‑
matic comedication in a large adult cohort of such 
patients.
PATIENTS AND METHODS Study participants We 
recruited consecutive patients with epilepsy who 
visited the outpatient epilepsy clinic at  least 
twice at the Department of Neurology, Univer‑
sity Hospital, Kraków, Poland, between January 
2017 and November 2018. The inclusion criteri‑
on was the diagnosis of epilepsy established ac‑
cording to the guidelines of International League 
Against Epilepsy.10 The exclusion criteria were lack 
of informed consent and coexistence of psycho‑
genic nonepileptic seizures.
Methods This study had a cross ‑sectional de‑
sign. Data from medical history were collected 
and then updated prospectively. An initial in‑
terview was structured and comprised the ques‑
tionnaire that included information on age, sex, 
age at the diagnosis of epilepsy, duration of epi‑
lepsy, as well as the type(s) and frequency of sei‑
zures. The types of epilepsy (focal, generalized, 
combined, or unknown) were defined in line 
with the recent International League Against 
TABLE 1 General characteristics of studied patients with epilepsy and current 
treatment of epilepsy
Variable Value
Female sex 380 (59.7)
Age, y, mean (SD) 35.3 (13.6)
Age at onset of epilepsy, y, mean (SD) 19.5 (14.6)
Mean duration of epilepsy, y, mean (SD) 15.8 (11.7)
Epilepsy type Generalized 139 (21.8)
Focal 478 (75.2)
Combined (generalized and focal) 
or unknown
19 (3)
Frequency of seizures >1 per month 229 (36.0)
1–12 per year 166 (26.1)
<1 per year 241 (37.9)
Number of currently used AEDs 1 350 (55.0)
2 208 (32.7)
3 72 (11.3)
4 9 (1.0)
Number of currently used AEDs, median (range) 1 (1–4)
The most commonly used AEDs 
(in mono ‑ or polytherapy)
Valproate 316 (49.7)
Levetiracetam 215 (33.8)
Lamotrigine 141 (22.2)
Carbamazepine 127 (20.0)
Topiramate 67 (10.5)
Oxcarbazepine 49 (7.7)
Data are presented as number (percentage) unless otherwise indicated.
Abbreviations: AEDs, antiepileptic drugs
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included levothyroxine (40, 6.3%), metoprolol 
(26, 4.1%), simvastatin (25, 3.9%), atorvastatin 
(25, 3.9%), acetylsalicylic acid (23, 3.6%), am‑
lodipine (19, 2.9%), perindopril (13, 2.1%), and 
ethinyl estradiol (15, 2.3%). In addition, 92 pa‑
tients (14.5%) took antipsychotics, antidepres‑
sants, and/or anxiolytics, but they were not in‑
cluded in the analysis. Three patients demonstrat‑
ed excessive polypharmacy with 10 AEDs or more 
and non ‑AEDs.
Somatic comorbidities in patients with epilepsy risk 
factors We compared patients with and with‑
out somatic comorbid conditions in terms of age, 
sex, age at onset of epilepsy, duration and type of 
epilepsy, seizure frequency, number of currently 
used AEDs, and type of AEDs. Variables that were 
significant in the univariate analysis were includ‑
ed in the multivariate model. Logistic regression 
(TABLE 4) revealed several independent risk factors 
for somatic comorbidities in patients with epilep‑
sy: older age, shorter duration of epilepsy, low‑
er seizure frequency, and lower number of AEDs.
DISCUSSION In this prospective, single ‑center 
study, we reported the frequency of somatic co‑
morbidities in a large cohort of adult patients with 
epilepsy. At least one co ‑occurring somatic con‑
dition was found in 216 patients (3%). The most 
common comorbidities were allergies, hyperten‑
sion, migraine, and hyperlipidemia.
Similar to a Canadian study by Tellez ‑Zenteno 
et al,8 the most common comorbidity in our study 
was allergy. However, it should be considered 
rather as a symptom and not as a single disor‑
der.8 In this study, we included a wide range of 
food, contact, seasonal, and drug allergies. Fur‑
thermore, AEDs are a well ‑known class of medica‑
tions causing idiosyncratic reactions.14 The most 
common AEDs in this study were valproate, leve‑
tiracetam, lamotrigine, and carbamazepine. Val‑
proate and levetiracetam are rarely culprit drugs; 
however, lamotrigine and carbamazepine cause 
rash in up to 5% of patients. The frequent use of 
AEDs with an aromatic ring (carbamazepine, la‑
motrigine, and oxcarbazepine) in the study pop‑
ulation can partially explain the high percentage 
of patients with allergies. 
The high frequency of cardiovascular diseases 
and hyperlipidemia is consistent with the results 
of Canadian and British studies.6,8 The relation‑
ship between cardiovascular diseases and epilepsy 
may be bidirectional. Ischemic brain tissue lesions 
are the common cause of epilepsy and acute symp‑
tomatic seizures.15 Furthermore, hepatic enzyme‑
‑inducing drugs are associated with the accelera‑
tion of atherosclerosis in patients with epilepsy.16 
The relatively low incidence of cardiovascular dis‑
eases in comparison with the general population 
can be partially explained by the young mean age 
of the studied patients.17,18 The prevalence of mi‑
graine in our cohort (9.3%) was higher than that 
reported by Gaitatzis et al6 (5.7% in patients in 
the age group of 16–64 years) and lower than that 
Prevalence of somatic comorbidities At least 1 co‑
morbid somatic condition was found in 216 pa‑
tients (34%). The most prevalent somatic comor‑
bidities were cardiovascular diseases, allergies, 
migraine, hyperlipidemia, thyroid disorders, and 
chronic lower respiratory diseases. The most com‑
mon conditions directly underlying epilepsy were 
brain tumors, stroke, and neurocutaneous syn‑
dromes. Data on the prevalence of somatic comor‑
bidities in the study group are provided in TABLE 2.
Use of medication for somatic disorders A total of 
200 patients (31.4%) were prescribed at least 1 
medication for somatic disorders. The majority of 
patients took 1 (87, 43.5%), 2 (55, 27.5%), or 3 
(23, 11.5%) medications. TABLE 3 shows the catego‑
ries of the Anatomical Therapeutic Chemical clas‑
sification system of somatic medications chron‑
ically used by the studied patients. The 10 most 
commonly used medications other than AED(s) 
TABLE 2 The most common somatic comorbidities in patients with epilepsy
Chronic somatic comorbidities Value
Allergies 131 (20.6)
Hypertensive disorders 101 (15.9)
Migraine 59 (9.3)
Hyperlipidemia 49 (7.7)
Thyroid disorders 42 (6.6)
Chronic lower respiratory diseases 41 (6.4)
Brain tumors 33 (5.1)
Other types of heart disease 31 (4.9)
Disorders of the esophagus, stomach, and duodenum 26 (4.1)
Stroke 24 (3.8)
Ischemic heart disease 15 (2.4)
Chronic kidney disease 15 (2.4)
Neurocutaneous syndromes 11(1.7)
Dermatitis and eczema 9 (1.4)
Diabetes mellitus 9 (1.4)
Comorbidities prevalent in <1% of patients (in alphabetic order) 
Acromegaly and pituitary gigantism
Addison disease
Chronic viral hepatitis
Dementia
Gaucher disease
Hemophilia A
Human immunodeficiency virus infection
Prostatic hyperplasia
Hyperprolactinemia
Osteoarthritis
Parkinsonism
Polycystic ovary syndrome
Psoriasis
Sarcoidosis
Systemic connective tissue disorders
Vitamin B12 deficiency anemia
Data are presented as number (percentage).
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Somatic comorbidities lead to premature mor‑
tality or disability and to increased health care 
costs in patients without epilepsy. Epilepsy itself 
accounts for a significant proportion of the dis‑
ease burden worldwide, as well as strongly affects 
patients’ independence, psychological health, and 
social life. Somatic comorbidities add to the bur‑
den of epilepsy, and their early detection and 
treatment may increase health ‑related quality of 
life in patients with epilepsy.22,23
Logistic regression analysis identified several 
independent risk factors for somatic comorbid‑
ities. Older patients were more likely to suffer 
from coexisting conditions, which is in line with 
the results of Gaitatzis et al,6 Adebayo et al,24 and 
Stefan et al.25 Surprisingly, patients with shorter 
duration of epilepsy, less frequent seizures, and 
taking fewer AEDs were at higher risk of having 
at least 1 comorbidity. We are not able to provide 
a clear explanation for this finding. There may be 
several reasons for this association. In pharmaco‑
resistant cases, the neurologist–patient interac‑
tion focuses on seizure frequency and treatment 
as well as on searching for possible coexisting 
conditions. However, other health care providers 
and patients themselves are prone to attribute all 
complaints to epilepsy and AEDs. Underdiagno‑
sis and undertreatment of both somatic and psy‑
chiatric disorders is a well ‑known phenomenon 
in patients with epilepsy.26-28
We must acknowledge some limitations of this 
study. First, there was no control group. Second, 
we studied the population of a university epi‑
lepsy clinic, which may differ substantially from 
the general population of patients with epilep‑
sy with regard to seizure frequency, treatment 
of epilepsy therapy, frequency of comorbidities, 
and use of concomitant medication. Third, some 
rare conditions resulting in pharmacoresistant ep‑
ilepsy may be overrepresented in our cohort, and 
patients with multiple comorbidities seen with‑
in the university hospital are frequently referred 
to our clinic. Finally, we focused on somatic co‑
morbidities. Psychiatric comorbidities and come‑
dication in Polish patiens with epilepsy were an‑
alyzed previously.20
In conclusion, our findings highlight the high 
prevalence of somatic comorbidities and comedi‑
cation with non ‑AEDs among patients with ep‑
ilepsy. Both were found in one ‑third of the rela‑
tively young cohort of adult patients. Neurolo‑
gists and other health care providers should in‑
crease their efforts to actively screen such pa‑
tients for somatic comorbidities. Patients with 
pharmacoresistant epilepsy may be at greater risk 
of underdiagnosis and undertreatment of these 
comorbidities. The presence of comorbid condi‑
tions may have implications for the diagnosis and 
treatment of seizure disorder and coexisting con‑
dition. Further prospective studies are needed to 
determine risk factors for somatic comorbidities 
in patients with epilepsy.
of Tellez ‑Zenteno et al8 (17%). This discrepancy 
can be explained by the fact that the diagnosis of 
migraine in the Polish cohort was established by 
a neurologist (MB) according to the Internation‑
al Headache Society criteria and was not based 
on data from general practices or population‑
‑based surveys.19
One ‑third of the patients were prescribed 
at least 1 medication for somatic disorders. How‑
ever, in this study, we aimed to evaluate the pres‑
ence of comorbidities and we did not focus on 
non ‑AEDs. The number of comedications, risk 
of seizure aggravation, and potential interaction 
between AEDs and non ‑AEDs in Polish patients 
have been described elsewhere.20,21
TABLE 3 Medications chronically used by patients with epilepsy as categorized by 
the Anatomical Therapeutic Chemical classification system
Medications classified according to ATC Value
Alimentary tract and 
metabolism (A)
Drugs for acid ‑related disorders (A02) 22 (3.5)
Drugs used in diabetes (A10) 9 (1.4)
Vitamins (A11) 5 (0.8)
Other alimentary tract and metabolism 
products (A16)
7 (1.1)
Blood and blood ‑forming 
organs (B)
Platelet aggregation inhibitors (B01AC) 23 (3.6)
Anticoagulants (B01AA or B01AE or 
B01AF)
10 (1.6)
Cardiovascular system (C) Diuretics (C03) 21 (3.3)
β‑Blockers (C07) 54 (8.5)
Calcium channel blockers (C08) 24 (3.7)
ACEIs (C09A) 35 (5.5)
Angiotensin II antagonists (C09C) 15 (2.4)
Lipid ‑modifying agents (C10) 49 (7.7)
Genito ‑urinary system and 
sex hormones (G)
Progestogens and estrogens (fixed 
combinations) (G03AA)
23 (3.6)a
Systemic hormonal 
preparations excluding sex 
hormones and insulins (H)
Systemic corticosteroids (H02) 5 (0.8)
Thyroid therapy (H03) 40 (6.3)
Antineoplastic and immunomodulating agents (L) 4 (0.6)
Musculoskeletal system (M) 4 (0.6)
Respiratory system (R) Drugs for obstructive airway diseases 
(R03)
20 (3.3)
Various (V) 15 (2.4)
Data are presented as number (percentage).
a A total of 17 patients used hormonal contraception.
Abbreviations: ACEI, angiotensin ‑converting enzyme inhibitor; ATC, Anatomical 
Therapeutic Chemical classification system
TABLE 4 Risk factors for somatic comorbidities in patients with epilepsy (logistic 
regression)
Parameter OR 95% CI P value
Sex 0.86 0.59–1.27 0.46
Age 1.08 1.07–1.10 <0.001
Duration of epilepsy 0.97 0.96–0.99 0.003
Seizure frequency 0.76 0.59–0.98 0.03
Number of AEDs 0.66 0.48–0.91 0.01
Abbreviations: AED, antiepileptic drug; CI, confidence interval; OR, odds ratio
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19 The International Classification of Headache Disorders 3rd edition. IHS 
Classification ICHD ‑3 website. https://www.ichd ‑3.org/. Accessed October 
16, 2018.
20 Bosak M, Cyranka K, Dudek D, et al. Psychiatric comedication in pa‑
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22 Poland. Institute for Health Metrics and Evaluation website. 
http://www.healthdata.org/poland. Accessed March 26, 2019.
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